Genetic Screening for Inflammation Response to Wood Smoke Particles
(SmokeScreen Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to study how people respond to wood smoke particles, with a focus on inflammation. Researchers are investigating whether a specific genetic trait, the GSTM1 null genotype, increases sensitivity to inflammation caused by wood smoke. The trial seeks both healthy volunteers and individuals with mild asthma who have experienced wheezing or chest tightness. Those with well-controlled asthma who do not require frequent medication might be suitable for this study. As an unphased trial, this study offers a unique opportunity to contribute to understanding how genetic traits affect inflammation response, potentially benefiting future treatments.
Do I need to stop taking my current medications for the trial?
If you have mild persistent asthma, you must stop taking Singulair, inhaled corticosteroids, or cromolyn for 2 weeks before the study visits, except for using cromolyn before exercise. Other medications may be allowed if they don't interfere with the study and have been stable for a month.
What prior data suggests that exposure to wood smoke particles is safe?
Research shows that breathing in wood smoke can irritate the lungs and cause inflammation. Some studies have found that even healthy individuals exposed to wood smoke might experience inflammation in their lungs and throughout their body. This exposure can upset the lungs and possibly weaken the immune system, increasing the likelihood of lung infections. Other research suggests that proximity to wood smoke might lead to more hospital visits for breathing issues. In some experiments, changes in genes related to inflammation have been observed, with differences noted between men and women. Additionally, studies on animals indicate that inhaling wood smoke can increase substances in the body that cause inflammation. While the safety of wood smoke remains under investigation, these findings suggest it can affect lung health.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to uncover how genetic factors influence inflammation responses to wood smoke particles. Unlike existing treatments that typically focus on alleviating symptoms of inflammation using medications like corticosteroids or NSAIDs, this study explores the underlying genetic mechanisms that might predict an individual's response to environmental pollutants. By identifying specific genetic markers, the trial could pave the way for personalized approaches to managing inflammation, potentially leading to more targeted and effective prevention strategies. This could be particularly groundbreaking for those with heightened sensitivity to air pollution, offering a new angle on prevention rather than just treatment.
What evidence suggests that this trial's treatments could be effective for inflammation response to wood smoke particles?
Research shows that inhaling wood smoke particles (WSP) can irritate the airways. Studies have found that these particles can activate the body's immune system, potentially leading to airway irritation. Evidence indicates that individuals with certain genetic traits, such as the GSTM1 null genotype, might be more susceptible to this irritation. Specifically, findings suggest that people with this genetic trait could face a higher risk of airway irritation when exposed to WSP. Overall, research supports that WSP can cause significant immune and irritation responses in some individuals. Participants in this trial will be exposed to WSP to study these effects further.46789
Who Is on the Research Team?
David B Peden, M.D., M.S.
Principal Investigator
Professor
Are You a Good Fit for This Trial?
This trial is for people aged 18-45 with mild asthma or allergies, who have good lung function and a low risk of cardiovascular disease. They must not smoke much, be willing to stop certain asthma medications temporarily, avoid caffeine before visits, and use reliable contraception if sexually active.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Woodsmoke Exposure
Participants are exposed to wood smoke particles to assess neutrophil responsiveness and the effect of the GSTM1 null genotype
Follow-up
Participants are monitored for changes in % neutrophils in induced sputum at 4 hours and 24 hours post-exposure
What Are the Treatments Tested in This Trial?
Interventions
- Wood Smoke Particles (WSP)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of North Carolina, Chapel Hill
Lead Sponsor
National Institute of Environmental Health Sciences (NIEHS)
Collaborator